Autor: |
Tomas, Milota, Karel, Kotaska, Petr, Lastuvka, Iveta, Klojdova, PID Clinical Group, Smetanova, Jitka, Bloomfield, Marketa, Zachova, Radana, Horvath, Rudolf, Sediva, Anna |
Předmět: |
|
Zdroj: |
Journal of Clinical Immunology; Feb2022, Vol. 42 Issue 2, p427-429, 3p |
Abstrakt: |
Twenty-three different autoantibodies were screened in 38 CVID patients receiving IRT (baseline characteristics in Supplementary table 1) and in the immunoglobulin solutions used for IRT (Supplementary table 2). We identified a high prevalence of anti-TPO autoantibodies and anti-GAD autoantibodies in the majority of the screened CVID patients receiving IRT. Despite the markedly impaired antibody production, diseases hallmarked by the presence of autoantibodies, such as autoimmune hemolytic anemia (AIHA) or immune thrombocytopenic purpura (ITP), are among the most commonly diagnosed autoimmune complications in CVID patients [[2]]. [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|